PubMed:7685420 JSONTXT

{"project":"DisGeNET","denotations":[{"id":"T0","span":{"begin":502,"end":511},"obj":"gene:2064"},{"id":"T1","span":{"begin":545,"end":566},"obj":"disease:C1739363"},{"id":"T2","span":{"begin":428,"end":437},"obj":"gene:2064"},{"id":"T3","span":{"begin":545,"end":566},"obj":"disease:C1739363"},{"id":"T4","span":{"begin":664,"end":673},"obj":"gene:2064"},{"id":"T5","span":{"begin":586,"end":610},"obj":"disease:C0007112"}],"relations":[{"id":"R1","pred":"associated_with","subj":"T0","obj":"T1"},{"id":"R2","pred":"associated_with","subj":"T2","obj":"T3"},{"id":"R3","pred":"associated_with","subj":"T4","obj":"T5"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer.\nPrevious reports have shown that Her-2/neu oncogene expression in human breast cancer and ovarian cancer may be associated with poorer prognosis. We report the expression of Her-2/neu on fresh samples of known prostatic adenocarcinoma but not on those of benign prostatic hypertrophy. Using a monoclonal antibody (TA1) directed against human Her-2/neu oncogene product and an immunohistochemical staining method, no Her-2/neu expression was noted with benign prostatic hypertrophy (15 samples). With prostatic adenocarcinoma samples, a subset (9 of 25) showed overexpression of Her-2/neu. Such overexpression is correlated with higher histological grade, higher stage of disease, and high S phase and aneuploidy on flow cytometric analysis. These findings suggest that Her-2/neu may be a prognostic marker in prostate cancer as well."}

{"project":"DisGeNET5_gene_disease","denotations":[{"id":"7685420-2#28#37#gene2064","span":{"begin":260,"end":269},"obj":"gene2064"},{"id":"7685420-2#64#88#diseaseC0007112","span":{"begin":296,"end":320},"obj":"diseaseC0007112"}],"relations":[{"id":"28#37#gene206464#88#diseaseC0007112","pred":"associated_with","subj":"7685420-2#28#37#gene2064","obj":"7685420-2#64#88#diseaseC0007112"}],"text":"Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer.\nPrevious reports have shown that Her-2/neu oncogene expression in human breast cancer and ovarian cancer may be associated with poorer prognosis. We report the expression of Her-2/neu on fresh samples of known prostatic adenocarcinoma but not on those of benign prostatic hypertrophy. Using a monoclonal antibody (TA1) directed against human Her-2/neu oncogene product and an immunohistochemical staining method, no Her-2/neu expression was noted with benign prostatic hypertrophy (15 samples). With prostatic adenocarcinoma samples, a subset (9 of 25) showed overexpression of Her-2/neu. Such overexpression is correlated with higher histological grade, higher stage of disease, and high S phase and aneuploidy on flow cytometric analysis. These findings suggest that Her-2/neu may be a prognostic marker in prostate cancer as well."}

{"project":"DisGeNet-2017-sample","denotations":[{"id":"T680","span":{"begin":119,"end":128},"obj":"gene:2064"},{"id":"T681","span":{"begin":158,"end":171},"obj":"disease:C0006142"},{"id":"T682","span":{"begin":176,"end":190},"obj":"disease:C0029925"}],"relations":[{"id":"R1","pred":"associated_with","subj":"T680","obj":"T681"},{"id":"R2","pred":"associated_with","subj":"T680","obj":"T681"},{"id":"R3","pred":"associated_with","subj":"T680","obj":"T682"},{"id":"R4","pred":"associated_with","subj":"T680","obj":"T682"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer.\nPrevious reports have shown that Her-2/neu oncogene expression in human breast cancer and ovarian cancer may be associated with poorer prognosis. We report the expression of Her-2/neu on fresh samples of known prostatic adenocarcinoma but not on those of benign prostatic hypertrophy. Using a monoclonal antibody (TA1) directed against human Her-2/neu oncogene product and an immunohistochemical staining method, no Her-2/neu expression was noted with benign prostatic hypertrophy (15 samples). With prostatic adenocarcinoma samples, a subset (9 of 25) showed overexpression of Her-2/neu. Such overexpression is correlated with higher histological grade, higher stage of disease, and high S phase and aneuploidy on flow cytometric analysis. These findings suggest that Her-2/neu may be a prognostic marker in prostate cancer as well."}

{"project":"sentences","denotations":[{"id":"TextSentencer_T1","span":{"begin":0,"end":85},"obj":"Sentence"},{"id":"TextSentencer_T2","span":{"begin":86,"end":231},"obj":"Sentence"},{"id":"TextSentencer_T3","span":{"begin":232,"end":370},"obj":"Sentence"},{"id":"TextSentencer_T4","span":{"begin":371,"end":580},"obj":"Sentence"},{"id":"TextSentencer_T5","span":{"begin":581,"end":674},"obj":"Sentence"},{"id":"TextSentencer_T6","span":{"begin":675,"end":826},"obj":"Sentence"},{"id":"TextSentencer_T7","span":{"begin":827,"end":919},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":85},"obj":"Sentence"},{"id":"T2","span":{"begin":86,"end":231},"obj":"Sentence"},{"id":"T3","span":{"begin":232,"end":370},"obj":"Sentence"},{"id":"T4","span":{"begin":371,"end":580},"obj":"Sentence"},{"id":"T5","span":{"begin":581,"end":674},"obj":"Sentence"},{"id":"T6","span":{"begin":675,"end":826},"obj":"Sentence"},{"id":"T7","span":{"begin":827,"end":919},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer.\nPrevious reports have shown that Her-2/neu oncogene expression in human breast cancer and ovarian cancer may be associated with poorer prognosis. We report the expression of Her-2/neu on fresh samples of known prostatic adenocarcinoma but not on those of benign prostatic hypertrophy. Using a monoclonal antibody (TA1) directed against human Her-2/neu oncogene product and an immunohistochemical staining method, no Her-2/neu expression was noted with benign prostatic hypertrophy (15 samples). With prostatic adenocarcinoma samples, a subset (9 of 25) showed overexpression of Her-2/neu. Such overexpression is correlated with higher histological grade, higher stage of disease, and high S phase and aneuploidy on flow cytometric analysis. These findings suggest that Her-2/neu may be a prognostic marker in prostate cancer as well."}

{"project":"UBERON-AE","denotations":[{"id":"PD-UBERON-AE-B_T1","span":{"begin":158,"end":164},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"}],"text":"Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer.\nPrevious reports have shown that Her-2/neu oncogene expression in human breast cancer and ovarian cancer may be associated with poorer prognosis. We report the expression of Her-2/neu on fresh samples of known prostatic adenocarcinoma but not on those of benign prostatic hypertrophy. Using a monoclonal antibody (TA1) directed against human Her-2/neu oncogene product and an immunohistochemical staining method, no Her-2/neu expression was noted with benign prostatic hypertrophy (15 samples). With prostatic adenocarcinoma samples, a subset (9 of 25) showed overexpression of Her-2/neu. Such overexpression is correlated with higher histological grade, higher stage of disease, and high S phase and aneuploidy on flow cytometric analysis. These findings suggest that Her-2/neu may be a prognostic marker in prostate cancer as well."}

{"project":"performance-test","denotations":[{"id":"PD-UBERON-AE-B_T1","span":{"begin":158,"end":164},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"}],"text":"Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer.\nPrevious reports have shown that Her-2/neu oncogene expression in human breast cancer and ovarian cancer may be associated with poorer prognosis. We report the expression of Her-2/neu on fresh samples of known prostatic adenocarcinoma but not on those of benign prostatic hypertrophy. Using a monoclonal antibody (TA1) directed against human Her-2/neu oncogene product and an immunohistochemical staining method, no Her-2/neu expression was noted with benign prostatic hypertrophy (15 samples). With prostatic adenocarcinoma samples, a subset (9 of 25) showed overexpression of Her-2/neu. Such overexpression is correlated with higher histological grade, higher stage of disease, and high S phase and aneuploidy on flow cytometric analysis. These findings suggest that Her-2/neu may be a prognostic marker in prostate cancer as well."}